Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Warren

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
The British Journal of Dermatology|October 26, 2011
Psoriasis comorbidities: a worldwide problem?R B Warren
Archives of Pathology & Laboratory Medicine|August 1, 1985
Papillary cystic tumor of the pancreasR B Warren
Journal of the European Academy of Dermatology and Venereology : JEADV|February 23, 2021
Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasisM Lebwohl, R B Warren
The British Journal of Dermatology|September 22, 2010
Systemic therapies containing ethanol and gelatine excipientsP M Laws, R B Warren
Journal of the Mississippi State Medical Association|May 11, 1975
Near-drowning: a complex pathophysiologic injuryB W Long, R B Warren
Arthritis and Rheumatism|April 3, 2008
Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: comment on the article by Wessels et alR B Warren, L J Gibbons
The British Journal of Dermatology|January 4, 2020
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisalA Al-Janabi, R B Warren
Expert Opinion on Biological Therapy|September 16, 2020
Update on risankizumab for the treatment of moderate to severe psoriasisA Al-Janabi, R B Warren
The British Journal of Dermatology|October 18, 2005
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasisR B Warren, C E M Griffiths
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm changeM Nogueira, R B Warren, T Torres
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|October 26, 2011
Psoriasis comorbidities: a worldwide problem?R B Warren
Archives of Pathology & Laboratory Medicine|August 1, 1985
Papillary cystic tumor of the pancreasR B Warren
Journal of the European Academy of Dermatology and Venereology : JEADV|February 23, 2021
Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasisM Lebwohl, R B Warren
The British Journal of Dermatology|September 22, 2010
Systemic therapies containing ethanol and gelatine excipientsP M Laws, R B Warren
Journal of the Mississippi State Medical Association|May 11, 1975
Near-drowning: a complex pathophysiologic injuryB W Long, R B Warren
Arthritis and Rheumatism|April 3, 2008
Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: comment on the article by Wessels et alR B Warren, L J Gibbons
The British Journal of Dermatology|January 4, 2020
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisalA Al-Janabi, R B Warren
Expert Opinion on Biological Therapy|September 16, 2020
Update on risankizumab for the treatment of moderate to severe psoriasisA Al-Janabi, R B Warren
The British Journal of Dermatology|October 18, 2005
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasisR B Warren, C E M Griffiths
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm changeM Nogueira, R B Warren, T Torres
Pageof 12